Evidence map›Paper›PMID 40050524›Full record

ArticleBreast cancer research and treatment2025

Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study.

Kelly E McCann, Noran Osman, Joan Cannon, Lonnie Brent, Yuexi Wang, Jon Tepsick, Prithviraj Vikramsinh Mandora, Vincent Miller, Nancy Martin, Virginia G Kaklamani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kelly E McCannDepartment of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California los Angeles, Los Angeles, CA, USA. kmccann@mednet.ucla.edu.ORCID http://orcid.org/0000-0001-8233-6242
Noran OsmanTerSera Therapeutics LLC, Deerfield, IL, USA.ORCID http://orcid.org/0009-0000-5630-874X
Joan CannonTerSera Therapeutics LLC, Deerfield, IL, USA.ORCID http://orcid.org/0009-0009-2410-7295
Lonnie BrentTerSera Therapeutics LLC, Deerfield, IL, USA.
Yuexi WangConcertAI, LLC, Cambridge, MA, USA.ORCID http://orcid.org/0009-0000-9455-5143
Jon TepsickConcertAI, LLC, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6035-7800
Prithviraj Vikramsinh MandoraConcertAI, LLC, Cambridge, MA, USA.
Vincent MillerConcertAI, LLC, Cambridge, MA, USA.ORCID http://orcid.org/0009-0006-0618-1211
Nancy MartinTerSera Therapeutics LLC, Deerfield, IL, USA.ORCID http://orcid.org/0009-0008-5706-4829
Virginia G KaklamaniUniversity of Texas Health Science Center San Antonio, San Antonio, TX, USA.ORCID http://orcid.org/0000-0002-3313-8458

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeClinical trials demonstrated every 3-month goserelin 10.8 mg to be non-inferior to monthly goserelin 3.6 mg in premenopausal patients with ER-positive breast cancer. However, real-world studies comparing 3-month goserelin 10.8 mg with monthly goserelin 3.6 mg are scarce.

methodsElectronic medical records from the ConcertAI Patient360™ database were analyzed in U.S. patients exposed to goserelin 3.6 mg or 10.8 mg post-breast cancer diagnosis. Inverse probability of treatment weighting (IPTW) was used to ensure the comparability between the two cohorts (goserelin 3.6 mg and goserelin 10.8 mg). The non-inferiority of goserelin 10.8 mg compared with goserelin 3.6 mg was assessed by 12-month real-world event-free survival (rwEFS) rates (- 15% margin) for the overall group of patients and separately for patients with early-stage/locally advanced and metastatic breast cancer.

resultsA total of 575 patients received goserelin 3.6 mg and 123 received goserelin 10.8 mg. Goserelin 10.8 mg was non-inferior to goserelin 3.6 mg based on observed 12-month rwEFS rates (79.2% versus 76.6%, respectively; treatment difference 2.7%). Goserelin 10.8 mg was observed to be non-inferior in patients who initiated goserelin in early-stage/locally advanced (treatment difference - 2.3%) and metastatic (treatment difference 10.4%) breast cancer.

conclusionThis real-world analysis indicates that 3-month goserelin 10.8 mg is non-inferior to monthly 3.6 mg among premenopausal women with breast cancer in terms of 12-month rwEFS rate. These findings may support the use of the 3-month goserelin 10.8 mg as an alternative treatment option to monthly goserelin 3.6 mg for this patient population.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsGoserelinAdultDelayed-Action PreparationsDrug Administration ScheduleFemaleHumansMiddle AgedNeoplasm StagingPremenopauseTreatment OutcomeUnited StatesAntineoplastic Agents, HormonalDelayed-Action PreparationsGoserelinBreast cancerEvent-free survivalGonadotropin-releasing hormone agonists (GnRHa)GoserelinPremenopausalReal-world evidence

Identifiers

PMID40050524
PMCPMC12006218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.